Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 125
- Locations
- 1
- Primary Endpoint
- Number of Patients Treatment Interruption
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this research is to understand how screening for patient resource needs followed by customized resource matching can improve outcomes for adults with breast, lung or gastrointestinal cancer.
Detailed Description
This research study is an intervention assessment; this is the first-time investigators are examining the impact of screening for resource needs followed by customized resource matching at Dana-Farber Cancer Institute. * The research study procedures include screening for social determinants of health (resource) needs and, depending on study group, resource matching. * Participants will be randomized into one of two groups. * Usual Care or Usual Care with customized resource matching. It is expected that about 125 participants will take part in this research study.
Investigators
Nadine McCleary, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
Inclusion Criteria
- •Eligible patients will be adults age 18 or older, able to consent, scheduled for a new patient consultation in DFCI BOC, TOP or GCC. To select for patients from demographic groups vulnerable to SDoH needs, two different groups will be eligible to participate.
- •BIPOC (Black, Latinx, Native American or Pacific Islander)
- •LEP Spanish-speaking (As indicated by the EHR)
- •Low SES (from zip code with median household income \<$32,000/year) OR
- •Any one NPIQ response indicating SDoH need
- •Health literacy/numeracy, Caregiving/relationships, OR Finances
Exclusion Criteria
- •Group A and B
- •- Patients not continuing care at Dana Farber Cancer Institute
Outcomes
Primary Outcomes
Number of Patients Treatment Interruption
Time Frame: 180 Days
Number of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)
Rate of Treatment Interruption
Time Frame: 180 Days
Rate of interruptions to cancer treatment (defined here as treatment hold, reduction, discontinuation or ED visits/hospitalizations as indicated by the patient medical record)